Ibandronate

SKU: orb1300679

Description

Ibandronate sodium monohydrate

Research Area

Cell Biology

Key Properties

• CAS Number: 138926-19-9
• MW: 359.23
• Purity: >98%
• Formula: C₉H₂₂NNaO₇P₂ • H₂O
• SMILES: O.[Na+].CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)([O-])=O
• Target: Apoptosis
• Solubility: Soluble in water (up to at least 25 mg/ml)

Bioactivity

• In Vivo:
  Ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months) significantly reduces the risk of new morphometric vertebral fractures by 62% and 50% (p = 0.0006), respectively, in osteoporotic women after 3 years' treatment. Ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months) significantly and progressively increases BMD of lumbar spine by 6.5% and 5.7%, respectively, in osteoporotic women after 3 years' treatment. Ibandronate (< 125 mg/kg s.c.) results in a dose dependent increase in bone mineral density (BMD), trabecular bone volume and trabecular number, load to failure (Fmax), and yield load in long bones and vertebrae in ovariectomized rats, and increased trabecular separation in ovariectomized rats is fully prevented by all doses.
• In Vitro:
  Ibandronate (1.25–2 μM) significantly reduces endothelial cell growth, while ibandronate (2 μM) also significantly reduces capillary-like tube formation and increases apoptosis of endothelial cells. Ibandronate (< 100 μM) dose-dependently increases VEGF expression in endothelial cells. Ibandronate (< 100 μM) inhibits growth of both prostate cancer cell lines (LNCaP and PC-3) in a dose dependent manner.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BM-21.0955

Compound Identifiers

PubChem CID

23663991